These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19934833)

  • 21. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
    Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
    Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 23. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
    Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
    Goldman DR; Baumal CR
    J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 23739589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab for retinopathy of prematurity.
    Good WV; Palmer EA
    N Engl J Med; 2011 Jun; 364(24):2359; author reply 2361-2. PubMed ID: 21675899
    [No Abstract]   [Full Text] [Related]  

  • 27. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
    Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [VEGF antibodies as therapy for retinopathy of prematurity].
    Oberacher-Velten IM; Helbig H
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.
    Quiroz-Mercado H; Martinez-Castellanos MA; Hernandez-Rojas ML; Salazar-Teran N; Chan RV
    Retina; 2008 Mar; 28(3 Suppl):S19-25. PubMed ID: 18317339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity.
    Shah PK; Narendran V; Tawansy KA; Raghuram A; Narendran K
    Indian J Ophthalmol; 2007; 55(1):75-6. PubMed ID: 17189897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-label use of bevacizumab in retinopathy of prematurity.
    Rishi E; Rishi P; Ratra D; Bhende M
    Retina; 2009 Feb; 29(2):284; author reply 284-5. PubMed ID: 18854784
    [No Abstract]   [Full Text] [Related]  

  • 32. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
    Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
    Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
    [No Abstract]   [Full Text] [Related]  

  • 33. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 34. Antivascular endothelial growth factor for retinopathy of prematurity.
    Mintz-Hittner HA; Best LM
    Curr Opin Pediatr; 2009 Apr; 21(2):182-7. PubMed ID: 19300261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Hosseini H; Khalili MR; Nowroozizadeh S
    Retina; 2009 Apr; 29(4):562. PubMed ID: 19262431
    [No Abstract]   [Full Text] [Related]  

  • 36. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Mintz-Hittner HA; Kuffel RR
    Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Present-day conservative treatment retinopathy of prematurity.
    Monika M; Katarzyna KK; Leszek K
    Klin Oczna; 2013; 115(1):65-8. PubMed ID: 23882745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
    dell'Omo R; Kulkarni A; Franks WA
    Acta Ophthalmol; 2008 Sep; 86(6):698-700. PubMed ID: 18081905
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.